HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Revlon

This article was originally published in The Rose Sheet

Executive Summary

Stephanie Klein-Peponis tapped as exec VP, chief marketing officer, effective immediately, Revlon announces. Exec promoted from role as exec VP, chief planning and business development officer, a position she has held since June (1"The Rose Sheet" June 2, 2003, In Brief). Klein-Peponis succeeds Chief Marketing Officer Debra Leipman-Yale, who is leaving the company after serving during a transitional period, firm notes...

You may also be interested in...



Revlon VP

Stephanie Klein Peponis to newly-created position of exec VP, chief planning and business development officer effective June 2, Revlon announces. Former VP and director of Boston Consulting Group will be responsible for supporting ongoing development and refinement of Revlon's business strategy, firm says. Reporting to CEO Jack Stahl, she will oversee planning processes, market research and analysis and evaluate new growth opportunities...

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS011545

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel